Business Context and Reporting Period
Palisade Bio, Inc. (PALI), a Delaware corporation, filed this Form 8-K on May 6, 2022, to report the entry into a material definitive agreement. The company is incorporated in Delaware and maintains its principal executive offices in Carlsbad, California.
Key Financial Metrics and Transaction Details
This filing details a "Hybrid Offering" consisting of a registered direct offering and a concurrent private placement. The filing does not provide historical revenue, profit, cash flow, or margin data.
- Registered Direct Offering: Sale of 3,646,690 shares of common stock at $0.55 per share.
- Concurrent Private Placement: Issuance of warrants to purchase up to 3,646,690 shares at an exercise price of $0.7105 per share.
- Placement Agent Warrants: Issuance of 218,801 warrants (6.0% of shares sold) to the placement agent at an exercise price of $0.7105 per share.
- Placement Agent Fees: Cash fee of 7.75% of aggregate gross proceeds plus expense reimbursement up to $85,000.
Material Changes
The primary material change is the dilution of existing shareholders through the issuance of new shares and warrants. The filing does not provide comparative financial metrics against a prior period as it reports a specific transaction event rather than periodic financial performance.
Outlook, Risks, and Unusual Items
Warrant Terms: Both the Purchase Warrants and Placement Agent Warrants are not exercisable until six months following issuance. The Purchase Warrants expire five and a half years from issuance, while the Placement Agent Warrants have a five-year term.
Regulatory Status: The shares were offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-263705), declared effective on April 26, 2022.
Management Commentary: The filing contains no forward-looking guidance or management commentary regarding future operations beyond the transaction details.
Key Facts for Investor Verification
- Verify the total gross proceeds raised from the sale of 3,646,690 shares at $0.55 per share.
- Confirm the net proceeds after deducting the 7.75% placement agent fee and up to $85,000 in expenses.
- Assess the potential dilution impact from the 3,646,690 Purchase Warrants and 218,801 Placement Agent Warrants exercisable at $0.7105.
- Review the full text of the Placement Agency Agreement (Exhibit 10.1) for additional terms not summarized in the 8-K.